Cancer Antigen 50

Description

Cancer Antigen 50
Catalog number: B2012256
Lot number: Batch Dependent
Expiration Date: Batch dependent
Amount: 25 kU
Molecular Weight or Concentration: 10,000 U/mL
Supplied as: Liquid
Applications: molecular tool for various biochemical applications
Storage: -20C
Keywords: CA-50, Cancer Antigen 50
Grade: Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um.

References:
1: Beauchemin N, Arabzadeh A. Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) in cancer progression and metastasis Cancer Metastasis Rev. 2013 Dec;32(3-4):643-71.
2: Zhang Y, Yu X, Liu Q, Gong H, Chen AA, Zheng H, Zhong S, Li Y. SAGE1: a Potential Target Antigen for Lung Cancer T-Cell Immunotherapy Mol Cancer Ther. 2021 Nov;20(11):2302-2313.
3: Persson BE, Ståhle E, Påhlman L, Glimelius B, Holmgren J. CA-50 as a tumour marker for monitoring colorectal cancer: antigen rises in patients postoperatively precede clinical manifestations of recurrence Eur J Cancer Clin Oncol. 1988 Feb;24(2):241-6.
4: Chen Z, Liu X, Shang X, Qi K, Zhang S. The diagnostic value of the combination of carcinoembryonic antigen, squamous cell carcinoma-related antigen, CYFRA 21-1, neuron-specific enolase, tissue polypeptide antigen, and progastrin-releasing peptide in small cell lung cancer discrimination Int J Biol Markers. 2021 Dec;36(4):36-44.
5: Li W, Jing Z, Wang S, Li Q, Xing Y, Shi H, Li S, Hong Z. P22 virus-like particles as an effective antigen delivery nanoplatform for cancer immunotherapy Biomaterials. 2021 Apr;271:120726.
6: Kuroki M, Matsushita H, Matsumoto H, Hirose Y, Senba T, Yamamoto T. Nonspecific cross-reacting antigen-50/90 (NCA-50/90) as a new tumor marker Anticancer Res. 1999 Nov-Dec;19(6C):5599-606.
7: Allard WJ, Neaman IE, Elting JJ, Barnett TR, Yoshimura H, Fritsche HA, Yeung KK. Nonspecific cross-reacting antigen 50/90 is elevated in patients with breast, lung, and colon cancer Cancer Res. 1994 Mar 1;54(5):1227-34.
8: Brezicka FT, Olling S, Bergman B, Berggren H, Engström CP, Hammarström S, Holmgren J, Larsson S, Lindholm L. Coexpression of ganglioside antigen Fuc-GM1, neural-cell adhesion molecule, carcinoembryonic antigen, and carbohydrate tumor-associated antigen CA 50 in lung cancer Tumour Biol. 1992;13(5-6):308-15.
9: Seelige R, Searles S, Bui JD. Innate sensing of cancer’s non-immunologic hallmarks Curr Opin Immunol. 2018 Feb;50:1-8.
10: Davis AA, Patel VG. The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors J Immunother Cancer. 2019 Oct 26;7(1):278.

Products Related to Cancer Antigen 50 can be found at Proteins